ad

Invicta Diagnostic IPO Listing Preview: What to Expect Now?

Fri Dec 05 2025

Invicta Diagnostic IPO Listing Preview: What to Expect Now?

Invicta Diagnostic IPO: The Invicta Diagnostic Limited listing is to be made on 8th December 2025. The IPO was opened for bidding from 1st December 2025 to 3rd December 2025. It is a bookbuilding IPO of ₹28.12 crores, comprising a fresh issue of 33,00,000 shares. The issue will be listed on NSE and SME on its tentative listing date, 8th December 2025. Scroll down to know more about Invicta Diagnostic IPO listing expectations.

Invicta Diagnostic IPO Listing Preview

As per the recent updates, the Invicta Diagnostic IPO listing could be made at around

₹85 per share on 8th December 2025. This conclusion is made based on Invicta Diagnostic GMP (grey market premium). However, the GMP and expected listing price are subject to change based on market sentiment. Stay informed with Univest to get live updates on the Complex Cinemas IPO listing or GMP trends. Scroll to explore the GMP of the Invicta Diagnostic IPO.

Invicta Diagnostic IPO GMP Grey Market Premium

GMP is the gap between the price band of the issue and the price at which company shares are currently trading in the grey market. Do you want to get live updates on the Invicta Diagnostic IPO? If yes, then you’ve reached the right spot. Check the table below to learn about the GMP trends.

GMP DateIPO PriceGMPEstimated Listing Price Estimated Listing Gains
5-12-2025₹85.00₹0.00₹85.000.00%
4-12-2025₹85.00₹0.00₹85.000.00%
3-12-2002₹85.00₹0.00₹85.000.00%
2-12-2025₹85.00₹0.00₹85.000.00%
1-12-2025₹85.00₹0.00₹85.000.00%
30-11-2025₹85.00₹0.00₹85.000.00%
29-11-2025₹85.00₹0.00₹85.000.00%
28-11-2025₹85.00₹0.00₹85.000.00%
27-11-2025₹85.00₹0.00₹85.000.00%

As of 5th December 2025, the Invicta Diagnostic IPO GMP stands at ₹0 per share. This means shares are likely to list at ₹85 on their tentative listing date, 8th December 2025.

GMP data is subject to change based on market conditions. You should check the live GMP status before applying for the Invicta Diagnostic IPO GMP. Stay informed with Univest for real-time insights into IPOs and their GMP trends.

Invicta Diagnostic  Limited Financials

The company’s financial analysis is essential before applying for the Invicta Diagnostic IPO. Look at the table to learn about Invicta Diagnostic  Limited’s financials. 

Year Ended30th September 2025 (in cr.)31st March 2025 (in cr.)31st March 2024 (in cr.)
Assets34.9021.2215.89
Revenue17.0830.1815.90
Profit After Tax4.084.933.81
EBITDA6.779.207.09
Net Worth23.6813.608.67
Reserves and Surplus14.425.188.54
Total Borrowing3.723.543.81

Explanation

Invicta Diagnostic  Limited’s revenue soared by 90% from ₹15.90 crores in March 2024  to ₹30.18 crores in March 2025. Moreover, the company’s PAT increased by 30% from ₹3.81 crores in March 2024 to ₹4.93 crores in March 2025.

How to Check Invicta Diagnostic IPO Allotment Status?

You can check for the Invicta Diagnostic IPO allotment in different ways. These include BSE and the registrar portal. Follow the steps below to check your allotment status online.

Check On NSE

  • Visit the NSE Official Site
  • Navigate to the IPO Allotment Section. 
  • Select Equity as the issue type. 
  • Choose the Invicta Diagnostic IPO.  
  • Choose whether to proceed with the PAN number or the application number.
  • Submit your details to get the allotment status online. 

Check On the Registrar Portal

  • Visit the registrar portal.
  • Click on the allotment option.
  • Fill in the required details.
  • Click on the submit button to know your Invicta Diagnostic IPO allotment status.

Recent Articles

HBL Engineering Q1 Results FY26: Q1 PAT Rises 78.87% to ₹143.27 Crore; Revenue Up 15.70% YoY

Fine Organic Q1 Results FY26: Q1 PAT Rose 7.04% to ₹117.10 Crore; Revenue Up 7.04% YoY

Eureka Forbes Q1 Results FY26: Q1 PAT Rises 20.32% to ₹38.68 Crore; Revenue Up 9.85% YoY

JM Financial Q1 Results FY26: Q1 PAT Rose 165.85% to ₹453.81 Crore; Revenue Up 3.18% YoY

IPCA Laboratories Q1 Results FY26: Q1 PAT Rises 21.31% to ₹233.21 Crore; Revenue Up 10.33% YoY